BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Mental Health
QHSLab, Inc. Launches a “Long COVID” Digital Health Tool for Primary Care Physicians
Primary care physicians now have access to reimbursable digital tools for the routine assessment of post-COVID conditions Strengthening QHSLab’s Business...
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23MADRID, Spain and BOSTON,...
CloudMD’s TAiCBT Results in Significant Improvement for PTSD Across Symptom Severity Levels, Trauma Types and Demographics
Recent research study demonstrates that the majority of clients experience reliable improvement in symptoms after just two months of treatmentVANCOUVER,...
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”),...
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™
Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive DisorderBURLINGTON, Mass. and JERUSALEM, Israel, Sept. 14, 2022 (GLOBE...
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for...
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa...
COMPASS Pathways to participate in three upcoming investor events
LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating...
MULTIMEDIA UPDATE — Social Threats to Aging Well in America: New Study Reveals Economic Instability, Loneliness, Food Insecurity as Top 3 Barriers to Senior Health
National survey from Alignment Healthcare explores issues preventing seniors from accessing care, provides insights into possible solutions Top 3 Social...
BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference
BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
Company encouraged by medicinal and therapeutic regulatory developments in Costa Rica Z Strain Psilocybe cubensis Optimi Health, Z Strain Psilocybe...
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health
Latest NeuroStar innovation to simplify the motor threshold determination for cliniciansMALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
RAMSAY SANTE :Update on the indicative offer received by Ramsay Health Care Limited
PRESS RELEASE Paris, August 26th 2022 Update on the indicative offer received by Ramsay Health Care Limited On 20 April...
Skylight Health Provides Clinical Research Update
Skylight Health Research continues to see success and trial awardsTORONTO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc....
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022...
Maximilian Doebler Appointed Chief Business Officer of HMNC Brain Health
MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry...
VitalHub Announces Licensing Agreement of Pre-Op Solutions, Synopsis Home and Synopsis iQ, to Bolton NHS Foundation Trust
TORONTO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI | OTCQX: VHIBF) is pleased...
InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Signs Five New Contracts, Adding more than 10,000 New Patients to its iUGO Care Platform
VANCOUVER, British Columbia, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...